Skip to main content

Table 2 Univariate analysis of influences of clinical characteristics and cytoplasmic and nuclear CD133 expression on OS and RFS in hepatocellular carcinoma patients

From: The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

  

OS

 

RFS

 

Characteristics

No.

Median survival (days)

Survival (%)

Log-rank

Median survival (days)

Survival (%)

Log-rank

Age (y/o)

 <65

64

1026

70.3%

0.330

999

67.2%

0.851

65

55

952

63.6%

 

952

63.6%

 

Gender

 Female

40

1007

70.0%

0.761

1007

67.5%

0.881

 Male

79

968

65.8%

 

954

64.6%

 

Differentiation

Moderate, Well

60

1047

70.0%

0.354

1026

70.0%

0.179

 Poor, Undifferentiation

57

937

64.9%

 

1003

60.4%

 

Stage

 I

42

1035

85.7%

0.003

1035

85.7%

0.001

 II, III

75

934

57.3%

 

921

54.7%

 

Hepatitis B surface antigen

 Negative

59

1003

69.5%

0.552

982

66.1%

0.861

 Positive

58

953

63.8%

 

937

63.8%

 

Hepatitis C virus

 Negative

75

934

62.7%

0.152

934

61.3%

0.189

 Positive

37

994

75.7%

 

955

73.0%

 

CD133 (Cytoplasm)

 Low

85

990

72.9%

0.022

990

72.9%

0.043

 High

34

943

52.9%

 

944

52.9%

 

CD133 (Nucleus)

 Low

71

946

59.2%

0.025

934

56.3%

0.013

 High

48

1100

79.2%

 

1076

79.2%